1073-P: Trends in Guideline-Directed Medication Therapy for Type 2 Diabetes in a Statewide Quality Collaborative between 2018–2023

Introduction and Objective: Since 2021, the Michigan Collaborative for Type 2 Diabetes (MCT2D) aims to improve guideline-directed medication therapies (GDMT) for type 2 diabetes (T2D). We examined trends in glucagon-like peptide-1 receptor agonist (GLP-1RA) and sodium-glucose transport protein 2 inhibitor (SGLT2i) prescribing rates comparing primary care (PC) and endocrinology (Endo) practices enrolled in MCT2D. Methods: We analyzed pharmacy claims data from adults with T2D insured by Blue Cross Blue Shield of Michigan Preferred Provider Organization and Medicare Advantage plans who received care in an MCT2D-participating practice (PC=300; Endo=19) between 2018-2023. Descriptive statistics were used to examine differences in pharmacy claims for anti-hyperglycemic medications. Results: From June 2022-June 2023, among 38,437 persons with T2D (PC=37,361; Endo=1,076), 26% and 41% had claims for GLP-1RA and 19% and 37% for SGLT2i, respectively. Compared to 2018 prescription rates, GLP-1RA increased by 17% and 22%, while SGLT2i prescriptions increased by 15% and 28% in PC and Endo practices respectively (Figure 1). Conclusion: Among practices participating in a statewide collaborative to improve treatment and outcomes for people with T2D, the use of GDMT has increased since 2018. SGLT2i use is similar and GLP-1RA use is 2-3-fold higher than rates reported in other studies. Disclosure K.R. Mizokami-Stout: None. L. Oshman: Stock/Shareholder; Procter GoodRx. Advisory Panel; Sanofi. Consultant; Tandem Diabetes Care, Inc. K.L. Khosrovaneh: None. N. Bhomia: None. N. Kim: None. J. Rau: None. J. Reiss: None. R. Busui: Board Member; American Diabetes Association. Consultant; Procter ADA/ACC Diabetes by Heart Program.